Author

J. Minnion

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 4 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

B. Jones· 5 shared S. R. Bloom· 5 shared A. Tomas· 4 shared M. Lucey· 4 shared D. Hodson· 3 shared G. A. Rutter· 3 shared P. Pickford· 3 shared B. M. Owen· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

B. Jones

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Intra-islet glucagon signalling regulates pulsatile insulin secretion and glucose homeostasis

K. Suba, Y. Patel, A. M. Alonso, A. Roberts, B. Hansen, M. Norton, J. Shrewsbury, R. Kwok, V. Kalogianni, S. Chen, X. Liu, G. A. Rutter, B. Jones, J. Minnion, B. M. Owen, , V. Salem

This study shows that loss of intra-islet glucagon receptor signaling impairs glucose tolerance and insulin pulsatility in mice, suggesting glucagonergic agents could restore insulin pulsatility in T2D.

bioRxiv · Sep 1, 2022 · PreprintPhysiology

Acylation of the incretin peptide exendin-4 directly impacts GLP-1 receptor signalling and trafficking

M. Lucey, T. Ashik, A. Marzook, Y. Wang, J. Goulding, A. Oishi, J. Broichhagen, D. Hodson, J. Minnion, Y. Elani, R. Jockers, S. J. Briddon, S. R. Bloom, A. Tomas, B. Jones

This study compares exendin-4 and its acylated variant exendin-4-C16, showing acylation affects GLP-1R signaling bias, trafficking, and pharmacokinetics.

bioRxiv · Apr 1, 2021Pharmacology & Toxicology

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

P. Pickford, M. Lucey, R.-M. Rujan, E. R. McGlone, S. Bitsi, F. Ashford, I. R. Correa, D. Hodson, A. Tomas, G. Deganutti, C. A. Reynolds, B. M. Owen, T. M. Tan, J. Minnion, S. R. Bloom, B. Jones

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

bioRxiv · Mar 2, 2021Pharmacology & Toxicology

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

M. Lucey, P. Pickford, J. Minnion, J. Ungewiss, K. Schoeneberg, G. A. Rutter, S. R. Bloom, A. Tomas, B. Jones

This study evaluates how C-terminal acylation affects GLP-1R signal bias and in vivo efficacy, finding that acylated ligands show improved therapeutic potential despite reduced potency.

bioRxiv · Nov 26, 2019Pharmacology & Toxicology

Differences in signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide

P. Pickford, M. Lucey, Z. Fang, S. Bitsi, J. Broichhagen, D. Hodson, J. Minnion, G. A. Rutter, S. R. Bloom, A. Tomas, B. Jones

This study compares the signalling, trafficking, and glucoregulatory effects of exendin-4 and lixisenatide, finding differences in cAMP signalling potency and receptor recycling that impact glucose control.

bioRxiv · Oct 16, 2019Pharmacology & Toxicology